ENHANCE and ONTARGET

Preventive Cardiology

Volumn 11, Issue 3, 2008, Pages 179-182

  Liebson, Philip R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIONEUROTIC EDEMA; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEART RATE; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SIDE EFFECT; SYNCOPE; TREATMENT DURATION; NOTE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 50549091800     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.07766.x     Document Type: Article

References (15)

1. Kastelein JJP, Akdim F, Stroes ESG, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
2. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam study. Circulation. 1997;96:1432-1437.
3. Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year post trial follow-up report from POSCH. Arch Intern Med. 1998;158:1253-1261.
4. Robinson JG, Smith B, Mahwshwari N, et al. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855-1862.
5. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): A prospective, randomized, double-blind trial. Lancet. 2001;357:577-581.
6. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358:1504-1507.
7. Drazen JM, Jarcho JA, Morrissey S, et al. Cholesterol lowering and ezetimibe. N Engl J Med. 2008;358:1507-1508.
8. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs. simvastatin only (study PO4103). http://clinicaltrials.gov/ct2/show/NCT00202878. Accessed April 6, 2008.
9. Devine PJ, Turco MA, Taylor AJ. Design and rationale of ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221-225.
10. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
11. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
12. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;352:145-153.
13. McMurray JJV. ACE inhibitors in cardiovascular disease-unbeatable? N Engl J Med. 2008;358:1615-1616.
14. Kaul S, Diamond GA. Good enough: A primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-69.
15. Pfeffer MA, McMurray JJV, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.